Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$25.33 +3.3%	$22.72	$13.40 ▼ $25.88	$4.14B	0.7	1.74 million shs	2.91 million shs
TGTX TG Therapeutics	$28.08 +1.1%	$35.07	$20.81 ▼ $46.48	$4.41B	1.95	2.82 million shs	1.81 million shs
VKTX Viking Therapeutics	$40.03 -0.5%	$31.10	$18.92 ▼ $81.73	$4.52B	0.67	4.64 million shs	3.29 million shs
XERS Xeris Biopharma	$7.68 +5.2%	$5.23	$2.48 ▼ $7.72	$1.18B	0.65	3.07 million shs	3.52 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	-2.48%	+0.53%	+11.45%	+10.20%	+62.02%
TGTX TG Therapeutics	-0.36%	-0.43%	-26.84%	-19.18%	+33.13%
VKTX Viking Therapeutics	-2.50%	+13.16%	+31.07%	+41.54%	-30.86%
XERS Xeris Biopharma	+0.34%	+10.61%	+38.00%	+49.59%	+186.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	3.9099 of 5 stars	3.3	2.0	0.0	2.6	4.2	2.5
TGTX TG Therapeutics	4.4322 of 5 stars	3.4	1.0	3.5	3.8	2.5	1.9
VKTX Viking Therapeutics	4.0818 of 5 stars	3.5	1.0	4.7	3.5	2.5	0.0
XERS Xeris Biopharma	3.4138 of 5 stars	1.4	3.0	4.2	3.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.61	Moderate Buy	$28.88	14.00% Upside
TGTX TG Therapeutics	2.75	Moderate Buy	$46.25	64.71% Upside
VKTX Viking Therapeutics	3.00	Buy	$86.92	117.14% Upside
XERS Xeris Biopharma	2.83	Moderate Buy	$6.58	-14.28% Downside

Current Analyst Ratings Breakdown

Latest XERS, VKTX, TGTX, and ACAD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	XERS Xeris Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$10.00
8/8/2025	ACAD ACADIA Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$32.00 ➝ $36.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	ACAD ACADIA Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$15.00 ➝ $17.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$39.00 ➝ $40.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $24.00
8/7/2025	ACAD ACADIA Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$37.00 ➝ $38.00
7/24/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $34.00
7/24/2025	VKTX Viking Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Strong-Buy ➝ Strong-Buy	$125.00 ➝ $122.00
7/24/2025	VKTX Viking Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$31.00 ➝ $38.00
7/10/2025	TGTX TG Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$37.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	4.46	$0.73 per share	34.80	$4.87 per share	5.20
TGTX TG Therapeutics	$329M	13.54	$0.12 per share	231.49	$1.74 per share	16.14
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$7.07 per share	N/A
XERS Xeris Biopharma	$203.07M	6.11	N/A	N/A	($0.12) per share	-64.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.33	19.05	33.33	6.24	21.80%	14.69%	9.41%	N/A
TGTX TG Therapeutics	$23.38M	$0.37	75.89	28.08	N/A	13.31%	26.05%	9.58%	11/3/2025 (Estimated)
VKTX Viking Therapeutics	-$109.96M	-$1.53	N/A	N/A	N/A	N/A	-19.98%	-19.38%	10/22/2025 (Estimated)
XERS Xeris Biopharma	-$54.84M	-$0.21	N/A	N/A	N/A	-13.01%	N/A	-8.00%	N/A

Latest XERS, VKTX, TGTX, and ACAD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	XERS Xeris Biopharma	-$0.03	-$0.01	+$0.02	-$0.01	$64.58 million	$67.71 million
8/6/2025	Q2 2025	ACAD ACADIA Pharmaceuticals	$0.14	$0.16	+$0.02	$0.16	$263.07 million	$264.57 million
8/4/2025	Q2 2025	TGTX TG Therapeutics	$0.32	$0.17	-$0.15	$0.17	$147.76 million	$141.15 million
7/23/2025	Q2 2025	VKTX Viking Therapeutics	-$0.44	-$0.58	-$0.14	-$0.58	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.91	2.83
TGTX TG Therapeutics	0.89	3.86	3.04
VKTX Viking Therapeutics	N/A	25.86	25.86
XERS Xeris Biopharma	N/A	1.95	1.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
TGTX TG Therapeutics	58.58%
VKTX Viking Therapeutics	76.03%
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.50%
TGTX TG Therapeutics	10.64%
VKTX Viking Therapeutics	4.10%
XERS Xeris Biopharma	6.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	168.71 million	124.00 million	Optionable
TGTX TG Therapeutics	290	158.67 million	141.78 million	Optionable
VKTX Viking Therapeutics	20	112.44 million	107.84 million	Optionable
XERS Xeris Biopharma	290	161.48 million	151.03 million	Optionable

XERS, VKTX, TGTX, and ACAD Headlines

Recent News About These Companies

Insider Selling: Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Sells 42,500 Shares of Stock

5 hours ago | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Purchases 418,139 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

August 15 at 4:28 AM | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Sells $309,400.00 in Stock

August 14 at 7:54 AM | insidertrades.com

Xeris Biopharma (NASDAQ:XERS) Rating Increased to Buy at HC Wainwright

August 14 at 2:13 AM | americanbankingnews.com

Xeris Biopharma's (XERS) "Buy" Rating Reaffirmed at HC Wainwright

August 13 at 8:35 AM | marketbeat.com

Informed Momentum Co LLC Grows Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

August 13 at 6:27 AM | marketbeat.com

Xeris Biopharma assumed with a Buy at H.C. Wainwright

August 12 at 5:49 PM | msn.com

Xeris Biopharma (XERS) Upgraded to Buy: Here's Why

August 12 at 1:01 PM | zacks.com

Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?

August 12 at 10:16 AM | zacks.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is Knott David M Jr's 7th Largest Position

August 12 at 8:17 AM | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Raised to Strong-Buy at Wall Street Zen

August 11, 2025 | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Releases Earnings Results, Beats Expectations By $0.02 EPS

August 10, 2025 | marketbeat.com

Critical Survey: Xeris Biopharma (NASDAQ:XERS) versus CASI Pharmaceuticals (NASDAQ:CASI)

August 10, 2025 | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Upgraded to "Strong-Buy" at Wall Street Zen

August 10, 2025 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Sees Strong Trading Volume After Better-Than-Expected Earnings

August 10, 2025 | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Sees Strong Trading Volume Following Better-Than-Expected Earnings

August 9, 2025 | marketbeat.com

Xeris Biopharma Holdings Second Quarter 2025 Earnings: Beats Expectations

August 9, 2025 | finance.yahoo.com

Xeris Biopharma (NASDAQ:XERS) Hits New 12-Month High After Earnings Beat

August 9, 2025 | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Hits New 12-Month High After Strong Earnings

August 8, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (XERS) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

August 7, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XERS, VKTX, TGTX, and ACAD Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$25.33 +0.80 (+3.26%)

Closing price 04:00 PM Eastern

Extended Trading

$25.33 0.00 (0.00%)

As of 07:55 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

TG Therapeutics NASDAQ:TGTX

$28.08 +0.31 (+1.12%)

Closing price 04:00 PM Eastern

Extended Trading

$28.09 +0.01 (+0.04%)

As of 07:44 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Viking Therapeutics NASDAQ:VKTX

$40.03 -0.21 (-0.52%)

Closing price 04:00 PM Eastern

Extended Trading

$40.70 +0.67 (+1.67%)

As of 08:00 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Xeris Biopharma NASDAQ:XERS

$7.68 +0.38 (+5.21%)

Closing price 04:00 PM Eastern

Extended Trading

$7.60 -0.08 (-1.04%)

As of 07:56 PM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time